Mark For: BRINTELLIX® trademark registration is intended to cover the categories of
Research |
![]() ![]() ![]() ![]() ![]() |
Serial Number | 88844656 |
Registration Number | 6255044 |
Mark Literal Elements | BRINTELLIX |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | TRADEMARK |
Register | PRINCIPAL |
Current Location | PUBLICATION AND ISSUE SECTION 2020-10-08 |
Basis | 44(e) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | No |
Filed ITU | No |
44D Filed | No |
44E Current | Yes |
66A Current | No |
Current Basis | No |
No Basis | No |
Domestic Representative | Claudia A. Smith |
Attorney Name | Claudia A. Smith |
Attorney Docket Number | LUNBECKBRINT |
2011-11-17 | Trademark Registered |
2020-03-23 | Application Filed |
2020-03-26 | Location: NEW APPLICATION PROCESSING |
2020-03-26 | Status: Live/Pending |
2020-03-26 | Transaction Date |
2020-10-08 | Location: PUBLICATION AND ISSUE SECTION |
2020-10-08 | Status: Review prior to publication completed. |
2020-11-10 | Published |
2021-01-26 | Trademark Registered |
Party: | ![]() |
Address | Ottiliavej 9 Valby DENMARK 2500 |
Legal Entity Type | Aktieselskab (a/s) |
Legal Entity State | DENMARK |
![]() | MULTI | 2020-03-23 |
![]() | JPEG | 2020-03-23 |
![]() | MULTI | 2020-04-30 |
![]() | MULTI | 2020-05-13 |
![]() | XML | 2020-06-13 |
![]() | XML | 2020-06-13 |
![]() | XML | 2020-10-06 |
![]() | MULTI | 2020-10-08 |
![]() | MULTI | 2020-10-09 |
![]() | XML | 2020-10-21 |
![]() | XML | 2020-10-21 |
IC 005. US 006 018 044 046 051 052. G & S: Vaccines; pharmaceutical preparations for treatment and prevention of central nervous system diseases and disorders; pharmaceutical preparations acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations for the treatment and prevention of dementia, Alzheimer's disease and disorder, dizziness, seizures, strokes, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety disorder, apathy disorder, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, balance disorders, movement disorders and diseases, dyskinesia, motor disorder, tremors, schizophrenia, bipolar disorder and disease, mania, Attention Deficit Hyperactivity Disorder, Post Traumatic Stress Disorder, agitated major depressive disorder, intermittent explosive disorder, autism, melancholic depression, tourette's syndrome, progressive supranuclear palsy (PSP), restless leg syndrome, akathisia, chronic fatigue syndrome, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency; diagnostic agents, preparations and substances for medical purposes
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Vaccines, pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system, pharmaceutical preparations and substances acting on the central nervous system, central nervous system stimulants, pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases, pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency, diagnostic agents, reagents, preparations and substances for medical purposes |
GS0051 | Vaccines; pharmaceutical preparations for treatment and prevention of central nervous system diseases and disorders; pharmaceutical preparations acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations for the treatment and prevention of dementia, Alzheimer's disease and disorder, dizziness, seizures, strokes, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety disorder, apathy disorder, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, balance disorders, movement disorders and diseases, dyskinesia, motor disorder, tremors, schizophrenia, bipolar disorder and disease, mania, Attention Deficit Hyperactivity Disorder, Post Traumatic Stress Disorder, agitated major depressive disorder, intermittent explosive disorder, autism, melancholic depression, tourette's syndrome, progressive supranuclear palsy (PSP), restless leg syndrome, akathisia, chronic fatigue syndrome, somnolence, nausea, cancer, headache, migraine, pain, alcoholism and chemical dependency; diagnostic agents, preparations and substances for medical purposes |
Description | Date | Proceeding Number |
---|---|---|
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-10-21 | |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-10-08 | |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-10-07 | 88889 |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2020-10-06 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-10-06 | 88889 |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2020-06-13 | 6325 |
NON-FINAL ACTION WRITTEN | 2020-06-13 | 93936 |
NON-FINAL ACTION E-MAILED | 2020-06-13 | 6325 |
ASSIGNED TO EXAMINER | 2020-06-13 | 93936 |
ASSIGNED TO LIE | 2020-05-12 | 73296 |
APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | 2020-05-12 | 73296 |
ASSIGNED TO LIE | 2020-05-04 | 74221 |
TEAS VOLUNTARY AMENDMENT RECEIVED | 2020-04-30 | |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2020-04-01 | |
NEW APPLICATION ENTERED IN TRAM | 2020-03-26 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.